Published in Vaccine Weekly, November 24th, 2010
pharmacogenetics in clinical drug discovery and development, and Astrimmune, which is focused on gastrointestinal cancers, are pleased to announce that they have entered into a collaboration to plan a biomarker identification programme. The plan, for Astrimmune's early-stage pancreatic cancer vaccine candidate, will be used in applications for further funding of its development. Financial terms were not disclosed.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly